Regulatory Bayer’s asundexian starts EU review for ischaemic stroke PharmaphorumThe EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.CardiovascularRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie’s migraine drug cleared for migraine attacks on NHSNext: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
